Application of an amyloid beta oligomer standard in the sFIDA assay

Application of an amyloid beta oligomer standard in the sFIDA assay

Still, there is need for significant improvements in reliable and accurate diagnosis for Alzheimer’s disease (AD) at early stages. It is widely accepted that changes in the concentration and conformation of amyloid-β (Aβ) appear several years before the onset of first symptoms of cognitive impairmen...

Full description

Bibliographic Details
Main Authors: Katja eKühbach, Maren eHülsemann, Yvonne eHerrmann, Kateryna eKravchenko, Andreas eKulawik, Christina eLinnartz, Luriano ePeters, Kun eWang, Johannes eWillbold, Dieter eWillbold, Oliver eBannach
Format: Article
Language:English
Published: Frontiers Media S.A. 2016-01-01
Series:Frontiers in Neuroscience
Subjects:
Alzheimer’s disease
early diagnosis
Amyloid-β peptide
Diagnostic biomarker
sFIDA
surface-based fluorescence intensity distribution analysis
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00008/full

Internet

http://journal.frontiersin.org/Journal/10.3389/fnins.2016.00008/full

Similar Items